Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab for Inflammation in Schizophrenia (IRIS)
NCT03093064Phase 1Completed
- Sponsor
- King's College London
- Start
- Apr 2017
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Natalizumab with Placebo (2 arms). Primary endpoint: Change in Translocator Protein (TSPO) availability pre- and post-natalizumab or placebo administration at Day 57. Started Apr 2017; status: completed.
02
Drugs
natalizumab
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03093064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093064.